Tragara Pharma, Inc.: Series A $40M

Tragara (San Diego, CA) a pharmaceutical company developing therapies for the treatment of lung cancer and inflammatory diseases closed a $40M Series A round. The financing was led by Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners and Mitsubishi International Corporation.

Sanarus Medical, Inc: Series E $15M

Sanarus Medical (Pleasanton, CA) provides minimally invasive products for the diagnosis and treatment of breast tumors closed a $15M Series E round. The deal was led by Easton Capital Partners and Mosaix Ventures and were joined by U.S. Venture Partners, Forward Ventures, Alta Partners, Federated Kaufmann Fund, Pequot Ventures, Industry Ventures and Channel Medical Partners.

ProteoGenix, Inc.: Series B $20M

ProteoGenix (Portland, OR) a diagnostics company utilizing high-throughput protein analysis techniques to identify protein biomarkers for pregnancy-related complications closed a $20M Series B round. The financing was led by New Leaf Venture Partners, TPG Growth and Burrill and Company.

Epiphany Biosciences, Inc.: Series A $36M

Epiphany Biosciences (San Francisco, CA) is developing both therapeutic products and diagnostic technologies that treat or prevent the spread of pathogenic viruses a new with its lead product for the treatment of Shingles closed a $36M Series A. The round was led by Wexford Capital other participants included Windsor Bay Capital, Global Trust Ventures Management and CDIB BioScience Venture Management.

Phenomix Corp.: Series C $55M

Phenomix (San Diego, Calif.) a drug discovery and development company focused on the treatment of Type 2 diabetes and hepatitis C raised a $55M Series C financing. The deal was led by Nomura Phase4 and joined by JPMorgan, Delphi Ventures, Baker Brothers, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and GBS Venture Partners.

Spaltudaq Corporation: Series B $29M

Spaltudaq (Seattle, WA) is focused on developing tumor-specific therapeutic antibodies for the treatment of cancer and infectious disease raised $29M in a Series B financing. The round was led by Arch Venture Partners and was joined by Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital and Alexandria Equities.

VentiRx Pharma, Inc.: Series A $26.6M

VentiRx Pharmaceuticals (Seattle, WA) a biopharmaceutical company focused on the development of medicines for the treatment of cancer and infectious, respiratory and autoimmune diseases, raised a $26.6M Series A round. The deal was led by Frazier Healthcare Ventures, ARCH Venture Partners and Domain Associates.

Transoma Medical, Inc.: Series C $13M

Transoma Medical (St. Paul, MN) maker of implantable wireless monitoring systems for patients with chronic cardiovascular disease closed a $13M Series C financing. The deal was led by Canaan Partners, Affinity Capital Management and Polaris Venture Partners.

PainCeptor Pharma Corp: Series B $20.8M

PainCeptor (Canada) a drug company focused on the treatment of chronic and acute pain raised a $20.8M Series B round. The deal was lead by Desjardins Venture Capital, CDP Capital, T2C2 Capital, Business Development Bank of Canada and Lothian Partners.

Intarcia Therapeutics, Inc.: Series B $50M

Intarcia Therapeutics (Emeryville, CA) a biopharmaceutical company developing therapies for Type 2 Diabetes and Hepatitis C raised $50M in a Series BB Financing. The round was led by New Leaf Venture, and joined by Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, and Granite Global Ventures.